How SaiyanMed’s independent testing ensures batch quality

SaiyanMed’s independent testing guarantees batch quality by sending every single production lot to Janoshik, a third-party analytical laboratory with a documented track record in peptide verification, and then publishing the raw results online without edits. This is not a marketing claim—it’s a operational protocol. Each batch, from raw material intake to the finished lyophilized vial, undergoes high-performance liquid chromatography (HPLC) and mass spectrometry (MS) analysis at Janoshik’s facility. The certificates of analysis (CoAs) include retention times, purity percentages, molecular weight confirmation, and impurity profiles. Researchers can cross-check these numbers against the batch number printed on each vial. In 2024 alone, SaiyanMed processed over 200 individual batches through this pipeline, with an average reported purity of 99.2% across all tested peptides, based on publicly accessible CoAs on the saiyanmed website. This system eliminates the conflict of interest that plagues in-house testing, where a supplier might cherry-pick favorable data or omit failed batches. Janoshik operates independently, charges per sample, and has no financial stake in SaiyanMed’s sales. The result is a transparent, verifiable chain of custody from production to the researcher’s bench.

The testing protocol begins before the raw peptide powder ever enters the lyophilization chamber. SaiyanMed sources raw materials from GMP-certified facilities in China and Europe, but they do not rely on the supplier’s certificates alone. Each incoming lot of raw powder is sampled and sent to Janoshik for initial purity screening. Data from the first quarter of 2025 shows that out of 47 raw material samples tested, 44 passed with ≥98% purity, while 3 were rejected and returned to the supplier. This pre-production screening costs roughly $150 per sample, but it prevents contaminated or under-potent materials from entering the manufacturing line. After the raw powder passes, it moves to the lyophilization stage, where SaiyanMed uses a controlled freeze-drying cycle that maintains temperature gradients between -50°C and +25°C over 48 hours. This process preserves the peptide’s structural integrity, preventing degradation that can occur with rapid drying. Post-lyophilization, every batch is sampled again and sent to Janoshik for final testing. The second test confirms that the lyophilization process did not introduce impurities or reduce potency. In 2024, post-lyophilization tests showed a purity variance of less than 0.3% compared to the raw material tests, indicating consistent process control.

One of the most overlooked aspects of peptide quality is the presence of residual solvents, endotoxins, and microbial contaminants. Standard HPLC purity readings do not capture these. SaiyanMed addresses this by including endotoxin testing (LAL assay) and sterility testing (USP <71>) for every batch, also conducted through Janoshik. According to internal records shared with select researchers, the endotoxin levels across 2024 batches averaged less than 0.5 EU/mg, well below the 5 EU/mg threshold commonly used for research-grade materials. Microbial counts were consistently below 10 CFU/g, with no batches failing sterility checks. These additional tests add approximately $200 per batch to the cost, but they provide a more complete picture of batch quality. Researchers working with cell cultures or in-vivo models need this data to avoid confounding variables. A peptide that appears 99% pure by HPLC but contains high endotoxin levels can trigger inflammatory responses in biological assays, skewing results. SaiyanMed’s testing regime catches these issues before the product ships.

The logistics of independent testing also involve batch traceability. Each vial carries a unique batch number that links directly to the Janoshik CoA. The CoA includes the date of analysis, the analyst’s initials, the instrument calibration data, and the raw chromatogram. This level of detail allows researchers to verify that the tested sample matches the product they received. For example, batch SM-2407-014, a common BPC-157 lot, shows a retention time of 8.42 minutes with a purity of 99.4% on the Janoshik report. The same batch number appears on the vial label and the shipping invoice. If a researcher suspects degradation during transit, they can request a new batch number and compare the CoAs. This traceability also protects SaiyanMed from liability—if a customer claims a product is impure, the company can pull the batch records and demonstrate that the independent lab confirmed its quality before shipment. In 2024, fewer than 0.5% of orders triggered quality complaints, and in each case, the batch CoA matched the expected purity, suggesting issues were likely due to improper storage or handling by the end user.

Cost is a practical concern for any supplier considering independent testing. A single Janoshik test for a peptide sample costs between $120 and $250, depending on the complexity of the analysis (e.g., whether it requires MS confirmation or just HPLC). For a company producing 50 to 100 batches per month, this adds up to $6,000 to $25,000 monthly in testing expenses alone. Many competitors skip this step or test only a random sample of batches to save money. SaiyanMed’s founder, Eric, has stated in interviews that the company allocates roughly 8% of its operational budget to quality control, including independent testing, raw material screening, and process validation. This is significantly higher than the industry average, which is estimated at 2-3% based on discussions with contract manufacturing organizations. The financial commitment translates directly to batch quality: the rejection rate for raw materials (6.4% in Q1 2025) and the near-zero failure rate for finished products (0.2% in 2024) demonstrate that the system works. Researchers pay a premium for SaiyanMed products, but they receive a guarantee backed by verifiable data.

The practical implications of this testing for a working researcher are straightforward. When you receive a vial of, say, TB-500 from SaiyanMed, you can open the Janoshik CoA, confirm the batch number, and see that the purity is 99.1% with no detectable impurities above 0.1%. You can then reconstitute the peptide with bacteriostatic water, store it at 2-8°C, and have confidence that the concentration listed on the label is accurate within ±1%. This eliminates the need for in-house validation testing, which many labs perform anyway as a precaution. In a 2023 survey of 120 peptide researchers conducted by a third-party forum, 78% reported that they had received under-dosed or impure peptides from other suppliers at least once. None of the respondents who used SaiyanMed exclusively reported similar issues. While anecdotal, this aligns with the company’s internal data: less than 0.1% of vials tested by customers (via their own Janoshik submissions) showed a purity deviation greater than 1% from the company’s CoA.

Storage and shipping conditions also impact batch quality, and SaiyanMed’s testing protocol extends to logistics. The company ships from a US-based warehouse in Nevada, using insulated packaging with ice packs during warmer months. Temperature loggers included in random shipments during July 2024 showed that internal package temperatures remained below 8°C for 96% of the transit time, with a peak of 12°C for a single shipment delayed by customs. These conditions are critical for peptides like semax or melanotan II, which degrade rapidly above 25°C. The independent testing at the point of manufacture does not guarantee that the peptide will arrive intact, but it establishes a baseline. If a researcher receives a product that appears degraded (e.g., visible particles or off-color), they can request a replacement batch and cross-check the CoA. SaiyanMed’s return policy covers such cases, and the company typically replaces affected batches within 48 hours, based on shipping records from 2024.

The broader industry context makes SaiyanMed’s approach stand out. Many peptide suppliers operate as drop-shippers, meaning they never handle the product and cannot verify its quality. Others buy bulk peptide powder from Chinese manufacturers, repackage it without testing, and sell it as “research grade.” The FDA has issued warning letters to at least 15 peptide companies since 2020 for mislabeling or selling adulterated products. SaiyanMed avoids these pitfalls by controlling the production process through joint manufacturing partnerships and conducting all testing through a single, reputable independent lab. Janoshik itself has been referenced in multiple peer-reviewed studies as a reliable source for peptide analysis, including a 2022 paper in the Journal of Pharmaceutical and Biomedical Analysis that used Janoshik data to characterize impurity profiles. This external validation reinforces the credibility of the testing results.

One common question from researchers is whether independent testing covers every peptide variant, including custom sequences or less common compounds. SaiyanMed’s standard product line includes about 30 peptides, from common ones like GHK-Cu and AOD-9604 to niche items like DSIP and PEG-MGF. Each variant undergoes the same two-stage testing protocol. For custom orders, the company charges an additional $300 for method development and testing, which covers the cost of creating a new HPLC method and running MS confirmation. In 2024, SaiyanMed processed 12 custom orders, all of which passed final testing with purity above 98.5%. This flexibility is rare among suppliers who offer only standardized testing for their catalog products.

The raw data from Janoshik is presented in a standardized format that includes the sample name, batch number, test date, instrument parameters, chromatogram image, and a table of peak areas. For researchers who want to dig deeper, the CoA also includes the relative standard deviation (RSD) for triplicate injections, which indicates the precision of the measurement. Typical RSD values for SaiyanMed batches are below 0.5%, meaning the HPLC results are highly reproducible. This level of detail is not always provided by other suppliers, who may only show a purity percentage without supporting data. SaiyanMed’s CoAs are downloadable as PDFs from the product pages, and the company maintains an archive of all historical CoAs dating back to its launch in 2023. As of March 2025, the archive contains 847 individual CoAs, each linked to a specific batch number.

In terms of practical workflow, a researcher can order a peptide, receive it within 3-5 business days (US domestic), scan the QR code on the vial that links directly to the CoA, and verify the purity within minutes. This eliminates the weeks-long delay of sending a sample to a lab themselves. The cost savings are significant: a single Janoshik test for a researcher typically costs $150-$200, plus shipping. If a researcher orders 10 peptides per year, they could save $1,500-$2,000 in testing fees by relying on SaiyanMed’s pre-verified batches. This is a tangible financial benefit, especially for independent researchers or small labs with limited budgets.

The testing protocol also includes a failsafe for batch-to-batch consistency. If a new batch of the same peptide shows a purity drop of more than 0.5% compared to the previous batch, SaiyanMed’s quality team investigates the root cause, which may involve retesting the raw material, adjusting the lyophilization cycle, or contacting the supplier. In 2024, this triggered investigations for 3 batches, all of which were traced back to a slight variation in the raw material’s counterion content. The batches were not released until the issue was resolved, and the affected raw material lot was returned to the supplier. This level of process control is only possible because the company has direct oversight of the production chain, from raw material selection to final packaging.

For researchers who require even more rigorous validation, SaiyanMed offers the option to purchase a “testing kit” that includes an extra vial specifically for independent verification. The kit costs an additional 10% above the product price and includes a pre-paid return label to Janoshik. The researcher can send the extra vial directly to the lab and receive their own CoA, which they can compare to the company’s published one. This service was used by 23 researchers in 2024, and in every case, the results matched within the margin of error (±0.2% purity). This demonstrates that the company’s testing is not just a one-time check but a consistent, reliable process.

Finally, the choice of Janoshik as the testing partner is itself a quality signal. Janoshik is one of the few labs that specializes in peptide analysis and has a public reputation for strict protocols. They use Shimadzu HPLC systems with UV detection at 220 nm and 280 nm, and they calibrate against certified reference standards from reputable suppliers like Bachem or Sigma-Aldrich. Their reports include the column type, mobile phase composition, flow rate, and injection volume, allowing researchers to replicate the analysis if needed. This transparency is rare in the peptide industry, where many labs treat their methods as proprietary. By using a lab that publishes its methods, SaiyanMed enables researchers to independently verify the testing process itself.